Our Vision

Harnessing Biomedical Signal Processing to Advance Medicine

At BioSig Technologies, we are dedicated to developing new ways to help patients and physicians. Our first product is the PURE EP™ System, a system designed for use in the large and growing electrophysiology market.

Learn More About BioSig

BioSig Chairman and CEO Ken Londoner on Solutions in Signal Processing

Listen to the latest podcast episode by SumZero Headlines

Press ReleaseFebruary 12, 2020

BioSig to Present at the 25th Annual International AF Symposium

PURE EP(tm) System to be highlighted in a Spotlight session by Andrea Natale, M.D., Texas Cardiac Arrhythmia Institute

Press ReleaseJanuary 21, 2020

BioSig to Commence Patient Cases at Mayo Clinic

Mayo Clinic is the second institution to conduct patient cases under BioSig’s clinical trial titled “Novel Cardiac Signal Processing System for Electrophysiology Procedures (PURE EP 2.0 Study)”. Patient enrollments are due to begin mid-January 2020. Texas Cardiac Arrhythmia Research Foundation (TCARF) in Austin, Texas, was the first institution to conduct patient cases under the clinical trial in the fourth quarter of 2019.

Press ReleaseJanuary 16, 2020

BioSig Awarded Additional US Patent Claims for its PURE EP(TM) System

The allowed patent application complements BioSig’s expanding patent portfolio, which now includes five allowed/issued patents. Eleven additional worldwide utility patent applications are pending covering various aspects of its PURE EP^TM System for recording, measuring, calculating and displaying of electrocardiograms during cardiac ablation procedures.

Press ReleaseJanuary 14, 2020

Bioelectronic Medicine:
The Leading Edge of Healthcare

Bioelectronic medicine is a new, rapidly growing field of healthcare that explores how targeted electrical signals in the body can help to diagnose and treat a wide range of diseases, from diabetes to depression.
BioSig aims to play a vital role in the field of bioelectronic medicine, based on our unique enabling technology and core competency in signal processing. Our initial focus is on heart disease and the fast-growing electrophysiology device market.

What Is Bioelectronic Medicine?

The Need to Improve Arrhythmia Treatment

Heart Disease Is the
#1 Cause of Death

Arrhythmia, a common cardiac condition, causes the heart to beat too quickly, too slowly, or erratically. New signal processing technologies could play a key role in enhancing outcomes from one of the most important treatments for arrhythmia: catheter ablation.

Challenging, Costly Conditions

The health and economic impacts of arrythmia are immense. The most common arrhythmia, atrial fibrillation (AFib), affects 33 million people worldwide* – generating annual healthcare costs of $15,000 to $25,000 per patient*.

*Worldwide Epidemiology of Atrial Fibrillation in the journal Circulation, 2013; “Healthcare Costs Drop Sharply after Successful Ablation,” Marlene Busko, Medscape, May 4, 2016

Barriers to Treatment Efficacy

Treatment of AFib and ventricular tachycardia typically starts with drug therapy, which is often ineffective, particularly in the later stages of heart disease. Catheter ablation often fails, leading to costly repeat procedures.

The Importance of Signal Clarity

Clearer signal information may help physicians work faster and more accurately during catheter ablation. One of the main reasons for low ablation success rates is unreliable information – specifically, the inability to differentiate between the clean signal and lab noise.

PURE EP™: A Signal Processing Solution

By improving signal clarity, BioSig’s PURE EP™ System has the potential to deliver valuable advances in electrophysiology procedures. We recently conducted first clinical cases at the Texas Cardiac Arrhythmia Institute under the leadership of Andrea Natale, M.D., F.A.C.C., F.H.R.S., F.E.S.C., Executive Medical Director, Texas Cardiac Arrhythmia Institute at St. David’s Medical Center. According to Dr. Natale, early results suggested improved cardiac signal detection and fidelity - click here to read the announcement.

How Does Pure EP™ Work?

Key Scientific Publications

We’re proud of our high success rate for peer-reviewed publications: 9 of the 10 publications we’ve submitted to date have been accepted. These publications provide early evidence that PURE EP™ could offer valuable improvements in signal clarity during electrophysiology procedures.

Browse Our Publications

Looking Beyond Arrhythmia

In 2017, BioSig signed a 10-year strategic collaboration with experts at Mayo Clinic to jointly develop our signal processing technology. These experts see the potential for our technology to help them electrically map the entire body, possibly leading to diagnosis and development of new therapies in other disease areas – for example, neurology and ophthalmology.

Learn About Our Partnerships

Creating Value for Investors

BioSig is a NASDAQ-traded company with a clear path to commercialization and growth, proven credentials for success, and a world-class leadership team. Check out our Investor Resources for financial and governance information, stock performance, SEC filings, and other materials.

See Investor Resources